ROS-responsive Polyethylenimine-phenylboronic acid-Bovine serum Albumin nanoparticles for targeted siMETTL3 delivery in hepatocellular carcinoma treatment | Synapse
May 15, 2026
ROS-responsive Polyethylenimine-phenylboronic acid-Bovine serum Albumin nanoparticles for targeted siMETTL3 delivery in hepatocellular carcinoma treatment
Key Points
This research aims to develop ROS-responsive nanoparticles for targeted delivery of siMETTL3 in treating hepatocellular carcinoma.
Developed nanoparticles using polyethylenimine, phenylboronic acid, and bovine serum albumin.
Targeted siMETTL3 delivery based on TME-specific ROS responsiveness.
Evaluated efficacy in hepatocellular carcinoma models.
Nanoparticles showed specific ROS responsiveness in targeting METTL3.
Enhanced therapeutic effect with significant reduction in tumor growth rates.
Improved targeting efficiency compared to conventional delivery systems.
Abstract
TME-specific ROS responsiveness, overcoming core bottlenecks in traditional METTL3 gene therapy.